| Literature DB >> 35333773 |
Fan Yuan1, Zhan Gu2, Yan Bi1, Ruixue Yuan1, Weibo Niu1, Decheng Ren1, Lei Zhang2, Guang He1, Bao-Cheng Liu2.
Abstract
BACKGROUND: Accumulated studies have pointed out the striking association between variants in or near APOC3, GCKR, PNPLA3, and nonalcoholic fatty liver disease (NAFLD) at various ages from multiple ethnic groups. This association remained unclear in the Chinese Han elderly population, and whether this relationship correlated to any clinical parameters was also unclear.Entities:
Keywords: GCKR; NAFLD; genetic association; mediation analysis; triglyceride
Mesh:
Substances:
Year: 2022 PMID: 35333773 PMCID: PMC9004570 DOI: 10.18632/aging.203970
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
The SNPs analyzed in this study.
|
|
|
|
|
|
|
|
|
| rs2854116 |
| Upstream | C>T | 11:116829453 | T=0.452 | C=0.470 | C=0.435 |
| rs2854117 |
| Upstream | T>A / T>C | 11:116829426 | C=0.499 | T=0.474 | T=0.432 |
| rs1260326 |
| Missense | T>C / T>G | 2:27508073 | C=0.293 | C=0.481 | C=0.453 |
| rs780094 |
| Intron | T>C | 2:27518370 | C=0.302 | C=0.476 | C=0.462 |
| rs780093 |
| Intron | T>C | 2:27519736 | C=0.292 | C=0.480 | C=0.467 |
| rs738409 |
| Missense | C>G / C>T | 22:43928847 | G=0.262 | G=0.350 | G=0.347 |
| rs2294918 |
| Missense | A>G | 22:43946236 | A=0.212 | A=0.192 | A=0.195 |
| rs2281135 |
| Intron | G>A / G>C | 22:43936690 | A=0.257 | A=0.364 | A=0.354 |
1The SNP Chromosome positions are based on the NCBI human genome build GRCh38.p12.
MAF_G, minor allele frequency in global; MAF_E, minor allele frequency in East Asian; MAF_P, minor allele frequency in present study.
Global and East Asian allele frequencies information was collected from 1000 genomes project [21].
Demographic and clinical characteristics of subjects.
|
|
|
| |
| Age (years) | 71.66 ± 6.394 | 71.47 ± 6.682 | 0.560 |
| BMI (kg/m2) | 24.28 ± 3.474 | 26.11 ± 3.269 | <0.001* |
| Gender (male, %) | 42.48 | 40.38 | 0.403 |
| Diabetes (%) | 20.63 | 25.10 | 0.036* |
| Hypertension (%) | 51.21 | 63.44 | <0.001* |
| Hypertriglyceridemia (%) | 40.86 | 55.14 | <0.001* |
| Hypercholesteremia (%) | 26.44 | 25.68 | 0.773 |
| Hyperuricemia (%) | 16.23 | 17.57 | 0.521 |
BMI, body mass index; *statistically significant.
Allelic distribution of SNPs between NAFLD and control.
|
|
|
|
|
|
|
|
| |
| rs2854116 | NAFLD | 826/640 | 0.436 | 0.69 | 0.023 | 1.011 | 0.879 | >0.999 |
| control | 933/715 | 0.433 | [0.87-1.16] | |||||
| C/T | ||||||||
| rs2854117 | NAFLD | 825/641 | 0.437 | 0.088 | 0.319 | 1.041 | 0.571 | >0.999 |
| control | 944/704 | 0.427 | [0.90-1.20] | |||||
| T/C | ||||||||
| rs1260326 | NAFLD | 829/637 | 0.434 | 0.759 | 3.735 | 0.869 | 0.053 | 0.424 |
| control | 875/773 | 0.469 | [0.75~1.00] | |||||
| T/C | ||||||||
| rs780094 | NAFLD | 816/650 | 0.443 | 0.541 | 3.906 | 0.867 | 0.048* | 0.384 |
| control | 859/789 | 0.478 | [0.75-0.99] | |||||
| T/C | ||||||||
| rs780093 | NAFLD | 808/659 | 0.448 | 0.541 | 3.639 | 0.871 | 0.056 | 0.448 |
| control | 852/796 | 0.485 | [0.75-1.00] | |||||
| C/G | ||||||||
| rs738409 | NAFLD | 952/514 | 0.35 | 0.655 | 0.175 | 1.032 | 0.674 | >0.999 |
| control | 1082/566 | 0.343 | [0.89-1.19] | |||||
| G/A | ||||||||
| rs2294918 | NAFLD | 1191/271 | 0.185 | 0.145 | 1.605 | 0.891 | 0.205 | >0.999 |
| control | 1308/334 | 0.203 | [0.74-1.06] | |||||
| G/A | ||||||||
| rs2281135 | NAFLD | 943/523 | 0.356 | 0.868 | 0.099 | 1.023 | 0.752 | >0.999 |
| control | 1069/579 | 0.351 | [0.88-1.18] |
MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; OR, odds ratio; CI, confidence interval; Pcorr, P value after Bonferroni correction; *statistically significant.
Figure 1Genotype frequency analysis in five genetic models. The genotype frequencies of rs1260326 and rs780094 were statistically different in the recessive model after Bonferroni correction.
GCKR rs1260326 genotype distributions in five genetic models.
|
|
|
|
|
|
|
|
|
|
| ||
| Codominant | T/T | 29.2 | 30.3 | 1 | 0.013* | 0.068 | 1 | 0.247 | >0.999 | ||
| T/C | 47.7 | 52.5 | 1.06 | [0.84-1.34] | 0.98 | [0.77-1.24] | |||||
| C/C | 23.1 | 17.2 | 0.72 | [0.54-0.96] | 0.69 | [0.51-0.93] | |||||
| Dominant | T/T | 29.2 | 30.3 | 1 | 0.654 | >0.999 | 1 | 0.291 | >0.999 | ||
| T/C+C/C | 70.8 | 69.7 | 0.95 | [0.77-1.18] | 0.89 | [0.71-1.11] | |||||
| Recessive | T/T+T/C | 76.9 | 82.8 | 1 | 0.003* | 0.020* | 1 | 0.007* | 0.035* | ||
| C/C | 23.1 | 17.2 | 0.69 | [0.54-0.89] | 0.7 | [0.54-0.91] | |||||
| Overdominant | T/T+C/C | 52.3 | 47.5 | 1 | 0.057 | 0.285 | 1 | 0.223 | >0.999 | ||
| T/C | 47.7 | 52.5 | 1.21 | [0.99-1.48] | 1.14 | [0.92-1.40] | |||||
| log-Additive | 0,1,2 | 52.9 | 47.1 | 0.87 | [0.75-1.00] | 0.052 | 0.261 | 0.84 | [0.73-0.98] | 0.025* | 0.125 |
In additive genetic model, genotypes were coded as 0, 1, or 2 according to the number of minor allele for a specific individual. P value after Bonferroni correction; *statistically significant.
1Associations were tested using logistic regression with adjustment for age, gender, and BMI.
Figure 2Levels of clinical parameters between rs1260326 CC and genotypes. TG level in carriers of rs1260326 T allele (1.94±1.19 mmol/L) was significantly higher than non-carriers (1.73±1.05 mmol/L). However, no marked difference of other clinical parameters was observed between the carriers and non-carriers of rs1260326 T allele (p > 0.05). ALP, alanine Phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; FPG, fasting plasma glucose; TC, total cholesterol; TG, triglyceride; SBP, systolic blood pressure; DBP, diastolic blood pressure; GGT, glutamyl transpeptidase; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; * p < 0.05. All data are represented as mean ± s.e.m.
GCKR rs780094 genotype distributions in five genetic models.
|
|
|
|
|
|
|
|
|
|
| ||
| Codominant | T/T | 27.9 | 29.2 | 1 | 0.018 | 0.09 | 1 | 0.022* | >0.999 | ||
| T/C | 48.4 | 52.9 | 1.05 | [0.83-1.32] | 0.97 | [0.77-1.24] | |||||
| C/C | 23.7 | 17.9 | 0.72 | [0.54-0.96] | 0.69 | [0.51-0.93] | |||||
| Dominant | T/T | 27.9 | 29.2 | 1 | 0.576 | >0.999 | 1 | 0.273 | >0.999 | ||
| T/C+C/C | 72.1 | 70.8 | 0.94 | [0.75-1.17] | 0.88 | [0.71-1.11] | |||||
| Recessive | T/T+T/C | 76.3 | 82.1 | 1 | 0.005 | 0.025* | 1 | 0.006* | 0.030* | ||
| C/C | 23.7 | 17.9 | 0.7 | [0.55-0.90] | 0.7 | [0.54-0.90] | |||||
| Overdominant | T/T+C/C | 52.9 | 47.1 | 1 | 0.076 | 0.38 | 1 | 0.211 | >0.999 | ||
| T/C | 48.4 | 52.9 | 1.2 | [0.98-1.46] | 1.14 | [0.54-0.90] | |||||
| log-Additive | 0,1,2 | 52.9 | 47.1 | 0.86 | [0.75-1.00] | 0.046 | 0.23 | 0.84 | [0.72-0.97] | 0.021* | >0.999 |
In additive genetic model, genotypes were coded as 0, 1, or 2 according to the number of minor allele for a specific individual. P value after Bonferroni correction; *statistically significant.
1Associations were tested using logistic regression with adjustment for age, gender, and BMI.
Figure 3Mediation of TG on the association between rs1260326 and NAFLD. Zero was not included in 95% confidence intervals representing statistical significance. TG, triglyceride; NAFLD, non-alcoholic fatty liver disease.
Figure 4Linkage disequilibrium plot between SNPs. The number in each square is r2*100 between two SNPs. As shown in the picture above rs1260326-rs780094-rs780093 was identified as a strong block with r2>0.8.